Last reviewed · How we verify

Inhaled Long-Acting Muscarinic Antagonist

Sanofi · Phase 3 active Small molecule

Inhaled Long-Acting Muscarinic Antagonist is a Long-acting muscarinic antagonist (LAMA) Small molecule drug developed by Sanofi. It is currently in Phase 3 development for Chronic obstructive pulmonary disease (COPD), Asthma (as add-on therapy).

Blocks muscarinic acetylcholine receptors in the airways to reduce bronchoconstriction and mucus secretion in chronic respiratory diseases.

Blocks muscarinic acetylcholine receptors in the airways to reduce bronchoconstriction and mucus secretion in chronic respiratory diseases. Used for Chronic obstructive pulmonary disease (COPD), Asthma (as add-on therapy).

At a glance

Generic nameInhaled Long-Acting Muscarinic Antagonist
SponsorSanofi
Drug classLong-acting muscarinic antagonist (LAMA)
TargetM3 muscarinic acetylcholine receptor
ModalitySmall molecule
Therapeutic areaRespiratory / Pulmonology
PhasePhase 3

Mechanism of action

Long-acting muscarinic antagonists (LAMAs) inhibit M3 muscarinic receptors on airway smooth muscle and mucus-secreting cells, preventing acetylcholine-induced contraction and secretion. When inhaled, they provide sustained bronchodilation over 24 hours, improving airflow and reducing symptoms in obstructive airway diseases. This mechanism is particularly effective in COPD and asthma where cholinergic tone contributes to airway obstruction.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Inhaled Long-Acting Muscarinic Antagonist

What is Inhaled Long-Acting Muscarinic Antagonist?

Inhaled Long-Acting Muscarinic Antagonist is a Long-acting muscarinic antagonist (LAMA) drug developed by Sanofi, indicated for Chronic obstructive pulmonary disease (COPD), Asthma (as add-on therapy).

How does Inhaled Long-Acting Muscarinic Antagonist work?

Blocks muscarinic acetylcholine receptors in the airways to reduce bronchoconstriction and mucus secretion in chronic respiratory diseases.

What is Inhaled Long-Acting Muscarinic Antagonist used for?

Inhaled Long-Acting Muscarinic Antagonist is indicated for Chronic obstructive pulmonary disease (COPD), Asthma (as add-on therapy).

Who makes Inhaled Long-Acting Muscarinic Antagonist?

Inhaled Long-Acting Muscarinic Antagonist is developed by Sanofi (see full Sanofi pipeline at /company/sanofi).

What drug class is Inhaled Long-Acting Muscarinic Antagonist in?

Inhaled Long-Acting Muscarinic Antagonist belongs to the Long-acting muscarinic antagonist (LAMA) class. See all Long-acting muscarinic antagonist (LAMA) drugs at /class/long-acting-muscarinic-antagonist-lama.

What development phase is Inhaled Long-Acting Muscarinic Antagonist in?

Inhaled Long-Acting Muscarinic Antagonist is in Phase 3.

What are the side effects of Inhaled Long-Acting Muscarinic Antagonist?

Common side effects of Inhaled Long-Acting Muscarinic Antagonist include Dry mouth, Headache, Tremor, Urinary retention, Tachycardia.

What does Inhaled Long-Acting Muscarinic Antagonist target?

Inhaled Long-Acting Muscarinic Antagonist targets M3 muscarinic acetylcholine receptor and is a Long-acting muscarinic antagonist (LAMA).

Related